Wild-type (senile) amyloidosis other diagnostic studies: Difference between revisions
No edit summary |
|||
| Line 26: | Line 26: | ||
!Genetic testing | !Genetic testing | ||
| | | | ||
* DNA sequencing for the transthyretin gene | *[[DNA]] sequencing for the [[transthyretin]] [[gene]] | ||
* Absence of amino acid sequence abnormalities by mass spectrometry is consistent with | * Absence of [[amino acid]] sequence abnormalities by [[mass spectrometry]] is consistent with wild-type (senile) amyloidosis | ||
* Presence of a pathologic mutation | * Presence of a [[Pathology|pathologic]] [[mutation]] | ||
** Predict sites of organ involvement | ** Predict sites of [[Organ (anatomy)|organ]] involvement | ||
** Family history | **[[Family history]] | ||
|} | |} | ||
Latest revision as of 19:13, 20 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies |
|
FDA on Wild-type (senile) amyloidosis other diagnostic studies |
|
CDC on Wild-type (senile) amyloidosis other diagnostic studies |
|
Wild-type (senile) amyloidosis other diagnostic studies in the news |
|
Blogs on Wild-type (senile) amyloidosis other diagnostic studies |
|
Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.
Other Diagnostic Studies
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.[1]
| Other Diagnostic Studies | |
|---|---|
| Histopathological analysis |
|
| Genetic testing |
|
References
- ↑ Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (December 2013). "Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis". Amyloid. 20 (4): 212–20. doi:10.3109/13506129.2013.825240. PMID 23964755.